Drug Profile
Sodium benzoate - SyneuRx
Alternative Names: Benzoate - SyneuRx; Clozaben; NaBen; SND 51; SND-11; SND-12; SND-13; SND-14; TannquilynneLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator SyneuRx International (Taiwan) corp
- Class Antidementias; Antifungals; Antipsychotics; Antiseptics; Benzoates
- Mechanism of Action D amino acid oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Schizophrenia
- Phase II Psychotic disorders
- No development reported Dementia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Dementia in USA (PO)
- 18 Apr 2022 Phase-II clinical trials in Psychotic disorders in USA (PO) (SyneuRx pipeline, April 2022)
- 18 Apr 2018 Phase-I clinical trials in Psychotic disorders in USA (PO) (SyneuRx pipeline, April 2018)